FGFR2 Human shRNA Plasmid Kit (Locus ID 2263)
CAT#: TG318702
FGFR2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
FGFR2 mouse monoclonal antibody, clone OTI5C5 (formerly 5C5)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | FGFR2 Human shRNA Plasmid Kit (Locus ID 2263) |
Locus ID | 2263 |
UniProt ID | P21802 |
Synonyms | BBDS; BEK; BFR-1; CD332; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25 |
Vector | pGFP-V-RS |
Format | Retroviral plasmids |
Kit Components | FGFR2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 2263). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
RefSeq | BC039243, NM_000141, NM_001144913, NM_001144914, NM_001144915, NM_001144916, NM_001144917, NM_001144918, NM_001144919, NM_001320654, NM_001320658, NM_022969, NM_022970, NM_022971, NM_022972, NM_022973, NM_022974, NM_022975, NM_022976, NM_023028, NM_023029, NM_023030, NM_023031, NR_073009, NM_000141.1, NM_000141.2, NM_000141.3, NM_000141.4, NM_022970.1, NM_022970.2, NM_022970.3, NM_001144913.1, NM_001144914.1, NM_001144915.1, NM_001144916.1, NM_001144917.1, NM_001144918.1, NM_001144919.1, NM_023029.1, NM_023029.2, BC039243.1, NM_022971.1, BC037338, BC096749, NM_001144919.2, NM_001144917.2, NM_000141.5 |
Summary | The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
,Kim, ST;Lee, IK;Rom, E;Sirkis, R;Park, SH;Park, JO;Park, YS;Lim, HY;Kang, WK;Kim, KM;Yayon, A;Lee, J;,
Am J Transl Res
,PubMed ID 31396354
[FGFR2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...